Bridgebio Pharma Financials
This page shows Bridgebio Pharma (BBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Bridgebio Pharma has an operating margin of -267.2%, meaning the company retains $-267 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -6528.7% the prior year.
Bridgebio Pharma's revenue surged 2285.3% year-over-year to $221.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
With a current ratio of 4.67, Bridgebio Pharma holds $4.67 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Bridgebio Pharma generated -$520.7M in operating cash flow, capex of $933K consumed most of it, leaving -$521.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Bridgebio Pharma passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Bridgebio Pharma generates $0.96 in operating cash flow (-$520.7M OCF vs -$543.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Bridgebio Pharma earns $-17.3 in operating income for every $1 of interest expense (-$593.0M vs $34.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Bridgebio Pharma generated $221.9M in revenue in fiscal year 2024. This represents an increase of 2285.3% from the prior year.
Bridgebio Pharma's EBITDA was -$586.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2.3% from the prior year.
Bridgebio Pharma generated -$521.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 1.4% from the prior year.
Bridgebio Pharma reported -$543.3M in net income in fiscal year 2024. This represents an increase of 16.8% from the prior year.
Bridgebio Pharma earned $-2.88 per diluted share (EPS) in fiscal year 2024. This represents an increase of 27.1% from the prior year.
Bridgebio Pharma held $681.1M in cash against $437.3M in long-term debt as of fiscal year 2024.
Bridgebio Pharma had 190M shares outstanding in fiscal year 2024. This represents an increase of 8.6% from the prior year.
Bridgebio Pharma's gross margin was 98.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 24.5 percentage points from the prior year.
Bridgebio Pharma's operating margin was -267.2% in fiscal year 2024, reflecting core business profitability. This is up 6261.5 percentage points from the prior year.
Bridgebio Pharma's net profit margin was -244.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 6777.1 percentage points from the prior year.
Bridgebio Pharma invested $506.5M in research and development in fiscal year 2024. This represents an increase of 11.1% from the prior year.
Bridgebio Pharma invested $933K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 28.6% from the prior year.
BBIO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $120.7M+9.2% | $110.6M-5.2% | $116.6M+1882.9% | $5.9M+171.3% | $2.2M-99.0% | $211.1M+11998.6% | $1.7M-57.3% | $4.1M |
| Cost of Revenue | $6.6M+79.7% | $3.7M+38.4% | $2.6M+26.6% | $2.1M+248.5% | $598K0.0% | $598K0.0% | $598K0.0% | $598K |
| Gross Profit | $114.1M+6.8% | $106.9M-6.2% | $114.0M+2901.4% | $3.8M+141.9% | $1.6M-99.3% | $210.5M+18254.1% | $1.1M-67.2% | $3.5M |
| R&D Expenses | $112.9M+1.5% | $111.2M-0.2% | $111.4M-14.5% | $130.3M+13.6% | $114.7M-18.6% | $141.0M+8.3% | $130.2M+4.1% | $125.1M |
| SG&A Expenses | $137.6M+6.6% | $129.2M+21.4% | $106.4M+12.2% | $94.8M+59.2% | $59.5M-9.5% | $65.8M+38.3% | $47.6M+33.0% | $35.8M |
| Operating Income | -$145.2M-8.1% | -$134.3M-28.7% | -$104.4M+53.8% | -$226.0M-28.8% | -$175.5M-51277.6% | $343K+100.2% | -$177.4M-12.5% | -$157.7M |
| Interest Expense | $11.7M+1.3% | $11.6M+20.8% | $9.6M+146.4% | -$20.7M-190.1% | $22.9M-2.3% | $23.5M+15.8% | $20.3M-0.2% | $20.3M |
| Income Tax | -$1.5M-173.6% | $2.1M | $0-100.0% | $1.2M | $0 | $0 | $0 | $0 |
| Net Income | -$184.9M-0.6% | -$183.8M-8.3% | -$169.6M+36.6% | -$267.4M-254.0% | -$75.5M-108.9% | -$36.2M+78.8% | -$170.3M+5.1% | -$179.5M |
| EPS (Diluted) | $-0.950.0% | $-0.95-8.0% | $-0.88+38.5% | $-1.43-266.7% | $-0.39-95.0% | $-0.20+79.4% | $-0.97+10.2% | $-1.08 |
BBIO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $998.3M-7.6% | $1.1B+22.5% | $881.6M-4.1% | $919.3M+15.7% | $794.4M-6.5% | $849.3M+55.4% | $546.4M-16.6% | $655.0M |
| Current Assets | $839.4M-8.0% | $912.3M+31.2% | $695.2M-3.5% | $720.7M+17.0% | $616.2M-21.3% | $783.4M+64.0% | $477.6M-18.7% | $587.7M |
| Cash & Equivalents | $643.0M-14.2% | $749.0M+38.5% | $540.6M-20.6% | $681.1M+67.0% | $408.0M-14.2% | $475.2M+26.4% | $375.9M-25.6% | $505.2M |
| Inventory | $24.5M+34.2% | $18.3M+362.2% | $4.0M | $0 | N/A | N/A | N/A | N/A |
| Accounts Receivable | $116.5M+51.6% | $76.9M-33.3% | $115.3M+2341.0% | $4.7M | N/A | N/A | $1.8M | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.9B+2.2% | $2.9B+13.4% | $2.5B+6.0% | $2.4B+26.7% | $1.9B-0.5% | $1.9B-0.1% | $1.9B+2.2% | $1.8B |
| Current Liabilities | $216.6M+23.2% | $175.9M+15.6% | $152.1M-1.5% | $154.4M+14.9% | $134.4M-5.0% | $141.5M-1.6% | $143.8M+35.6% | $106.1M |
| Long-Term Debt | $2.0B | $0 | $0-100.0% | $437.3M+0.4% | $435.4M+0.2% | $434.7M-2.6% | $446.4M+1.1% | $441.7M |
| Total Equity | -$1.9B-8.1% | -$1.8B-8.5% | -$1.6B-12.3% | -$1.5B-34.3% | -$1.1B-4.1% | -$1.0B+22.5% | -$1.4B-12.1% | -$1.2B |
| Retained Earnings | -$3.6B-5.3% | -$3.4B-5.6% | -$3.3B-5.4% | -$3.1B-16.0% | -$2.7B-2.8% | -$2.6B-1.4% | -$2.6B-7.0% | -$2.4B |
BBIO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$109.6M-35.8% | -$80.7M+59.5% | -$199.2M-2.0% | -$195.3M-361.5% | $74.7M+134.0% | -$219.5M-75.9% | -$124.8M+14.1% | -$145.2M |
| Capital Expenditures | $470K-20.9% | $594K | $0-100.0% | $47K-13.0% | $54K-92.2% | $695K+59.8% | $435K+0.9% | $431K |
| Free Cash Flow | -$110.0M-35.4% | -$81.3M+59.2% | -$199.2M-2.0% | -$195.4M-361.7% | $74.6M+133.9% | -$220.2M-75.8% | -$125.3M+14.0% | -$145.7M |
| Investing Cash Flow | $4.5M+134.3% | -$13.0M-715.2% | -$1.6M+50.7% | -$3.2M-206.5% | $3.0M-86.6% | $22.8M+34574.2% | -$66K-100.2% | $37.7M |
| Financing Cash Flow | -$894K-100.3% | $302.0M+400.7% | $60.3M-87.3% | $473.9M+8372.5% | -$5.7M-102.0% | $279.5M+6280.6% | -$4.5M-101.5% | $307.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0-100.0% | $48.3M | $0 | $0 | $0 | N/A | N/A |
BBIO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.6%-2.1pp | 96.7%-1.0pp | 97.7%+33.2pp | 64.6%-7.8pp | 72.4%-27.3pp | 99.7%+34.0pp | 65.7%-19.7pp | 85.4% |
| Operating Margin | -120.3%+1.1pp | -121.4%-32.0pp | -89.5%+3753.2pp | -3842.7%+4254.1pp | -8096.8%-8097.0pp | 0.2%+10167.3pp | -10167.1%-6312.5pp | -3854.6% |
| Net Margin | -153.2%+13.0pp | -166.2%-20.8pp | -145.4%+4400.5pp | -4545.9%-1061.4pp | -3484.5%-3467.4pp | -17.1%+9743.8pp | -9760.9%-5373.5pp | -4387.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -18.5%-1.5pp | -17.0%+2.2pp | -19.2%+9.8pp | -29.1%-19.6pp | -9.5%-5.3pp | -4.3%+26.9pp | -31.2%-3.8pp | -27.4% |
| Current Ratio | 3.88-1.3 | 5.19+0.6 | 4.57-0.1 | 4.67+0.1 | 4.59-1.0 | 5.54+2.2 | 3.32-2.2 | 5.54 |
| Debt-to-Equity | -1.04-1.0 | 0.000.0 | 0.00+0.3 | -0.30+0.1 | -0.40+0.0 | -0.41-0.1 | -0.33+0.0 | -0.37 |
| FCF Margin | -91.2%-17.7pp | -73.5%+97.3pp | -170.8%+3150.7pp | -3321.5%-6764.8pp | 3443.2%+3547.5pp | -104.3%+7073.6pp | -7177.9%-3617.5pp | -3560.4% |
Note: Shareholder equity is negative (-$1.5B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Bridgebio Pharma's annual revenue?
Bridgebio Pharma (BBIO) reported $221.9M in total revenue for fiscal year 2024. This represents a 2285.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bridgebio Pharma's revenue growing?
Bridgebio Pharma (BBIO) revenue grew by 2285.3% year-over-year, from $9.3M to $221.9M in fiscal year 2024.
Is Bridgebio Pharma profitable?
No, Bridgebio Pharma (BBIO) reported a net income of -$543.3M in fiscal year 2024, with a net profit margin of -244.9%.
What is Bridgebio Pharma's earnings per share (EPS)?
Bridgebio Pharma (BBIO) reported diluted earnings per share of $-2.88 for fiscal year 2024. This represents a 27.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Bridgebio Pharma's EBITDA?
Bridgebio Pharma (BBIO) had EBITDA of -$586.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bridgebio Pharma have?
As of fiscal year 2024, Bridgebio Pharma (BBIO) had $681.1M in cash and equivalents against $437.3M in long-term debt.
What is Bridgebio Pharma's gross margin?
Bridgebio Pharma (BBIO) had a gross margin of 98.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bridgebio Pharma's operating margin?
Bridgebio Pharma (BBIO) had an operating margin of -267.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Bridgebio Pharma's net profit margin?
Bridgebio Pharma (BBIO) had a net profit margin of -244.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Bridgebio Pharma's free cash flow?
Bridgebio Pharma (BBIO) generated -$521.7M in free cash flow during fiscal year 2024. This represents a 1.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bridgebio Pharma's operating cash flow?
Bridgebio Pharma (BBIO) generated -$520.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bridgebio Pharma's total assets?
Bridgebio Pharma (BBIO) had $919.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Bridgebio Pharma's capital expenditures?
Bridgebio Pharma (BBIO) invested $933K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Bridgebio Pharma spend on research and development?
Bridgebio Pharma (BBIO) invested $506.5M in research and development during fiscal year 2024.
How many shares does Bridgebio Pharma have outstanding?
Bridgebio Pharma (BBIO) had 190M shares outstanding as of fiscal year 2024.
What is Bridgebio Pharma's current ratio?
Bridgebio Pharma (BBIO) had a current ratio of 4.67 as of fiscal year 2024, which is generally considered healthy.
What is Bridgebio Pharma's debt-to-equity ratio?
Bridgebio Pharma (BBIO) had a debt-to-equity ratio of -0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bridgebio Pharma's return on assets (ROA)?
Bridgebio Pharma (BBIO) had a return on assets of -59.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bridgebio Pharma's cash runway?
Based on fiscal year 2024 data, Bridgebio Pharma (BBIO) had $681.1M in cash against an annual operating cash burn of $520.7M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Bridgebio Pharma's debt-to-equity ratio negative or unusual?
Bridgebio Pharma (BBIO) has negative shareholder equity of -$1.5B as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bridgebio Pharma's Piotroski F-Score?
Bridgebio Pharma (BBIO) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bridgebio Pharma's earnings high quality?
Bridgebio Pharma (BBIO) has an earnings quality ratio of 0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bridgebio Pharma cover its interest payments?
Bridgebio Pharma (BBIO) has an interest coverage ratio of -17.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bridgebio Pharma?
Bridgebio Pharma (BBIO) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.